EyePoint should be bought on recent weakness, says Mizuho

Mizuho recommends buying shares of EyePoint Pharmaceuticals on the recent weakness. The firm has a Buy rating on the shares with a $39 price target. The company made a series of incremental announcements yesterday, including the addition of three “experienced and high quality retinal specialists” to its scientific advisory board, the FDA’s conditional acceptance of a new trade name, Duravyu, for its lead asset, EYP-1901, and that it remains on track for its key upcoming catalysts in 2024, the analyst tells investors in a research note. The firm is “overall pleased by the various pieces of news.”